San Jose, CA (openPR) 24 March 2010

erectile dysfunction (ED) is the state in which a person is not able to achieve and maintain an erection sufficient for satisfactory sexual intercourse. It affects the lives of many middle-aged men and their partners worldwide. Erectile dysfunction can also be a sign of emotional or physical problem that treatment is necessary. Previously, ED would be a taboo subject and a very small percentage of men actively engaged in the treatment. But over time more people started to ask for help. Doctors also get a better understanding of the physiological and psychological causes of erectile dysfunction, which enable them to develop breakthrough treatments.

United States and Europe dominate the global market for drugs to treat erectile dysfunction, as indicated by the research about the marketing of new drugs for the treatment of erectile dysfunction. cause with increasing dependence on drugs, the side effects such as erectile dysfunction, a growing population of baby boomers, and various other categories of comorbidity, including depression, diabetes and cardiovascular patients, the U.S. market for drugs to treat erectile experienced a significant expansion. These figures are expected to see further growth in the country, paving the way for increased demand and stable yields. Because of the convenience and efficiency associated with oral prescription drugs they be the most common form of treatment for erectile dysfunction in Europe continues. The launch of new topical drugs, OTC and prescription would benefit the ED market expansion and paving the way for the development of advanced oral drugs.

There are several companies engaged in the development of treatments for erectile dysfunction. Although treatment options vary between oral treatments, implants, injections and topical treatments, oral medications continue to dominate the global market for ED drugs. Key players in the report include Abbott Laboratories, Eli Lilly and Company, Inc., F. Hoffmann-La Roche Inc., GlaxoSmithKline plc, Nexmed Inc., Pfizer Inc., Sanofi-Aventis SA, Vivus Inc. and Warner Chilcott Limited .

Report “Erectile dysfunction drugs: A Global Strategic Business Report, entitled” announced by Global Industry Analysts, Inc., a comprehensive review of market trends, competitive factors provides scenario, product overview, and recent activities of the industry. This study analyzes market data and analysis in terms of value sales for regions including the United States, Canada, Japan, Europe, and the world.

For more details on this report on the study of the market, please visit –

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a renowned publisher of off-market research in the trade. Founded in 1987, the company is recognized worldwide as one of the world’s largest market research publishers recognized. The company employs over 800 people worldwide and publishes more than 1,100 large-scale research reports each year. In addition, the company also offers thousands of research products including reports of small businesses, reports on market trends and industry reports include all major industries worldwide.


Industry analysts

Global, Inc.

Tel 408-528-9966

Fax 408-528-9977

email press (at) StrategyR (dot) com
>
Http://www.StrategyR.com/ website

P

###

clear = “all”
Erectile dysfunction